Summary The concentration of cellular fibronectin (cFN) containing the extra domain A (EDA) was measured in 479 plasma and 300 serum samples from healthy blood donors by a competitive enzyme immunoassay (EIA). Serum and plasma samples contained low concentrations of EDAcFN. The mean concentration of EDAcFN was higher in plasma (2.46mgl-') than in serum (0.30mg1-'). No significant differences between sexes or age groups were found. The EDAcFN concentrations were also measured in 120 patients with various malignancies. 
FNs are adhesive glycoproteins that have variable primary structures owing to cell type-specific splicing of FN precursor mRNA. FNs can be divided into two major groups: plasma (p) and cellular (c) forms. cFNs differ from pFN in having the so called extra domain (ED) sequences A or B in the molecule (Schwarzbauer, 1991) . Hepatocytes produce pFN. while cFNs are produced locally (Tamkun and Hynes, 1983) .
However, plasma also contains small quantities of cFN (Vartio et al., 1987) . All FNs can be found in soluble form and also deposited in pericellular matrices.
Numerous studies have shown that FNs have a role in various biological phenomena, such as cell adhesion, mobility and differentiation (Yamada et al., 1985) . Determining the concentration of FN in plasma appears useful in evaluating the status of the mononuclear phagocytic system (Mosher, 1980; Stathakis et al., 1981) . In many studies total FN in plasma and other body fluids has been evaluated as a marker for cancer or other diseases (Parsons et al., 1979a,b; Webb and Linn, 1980; Stathakis et al., 1981; Choate and Mosher, 1983; Siri et al., 1984; Boccardo et al., 1986; Ruelland et al., 1988; Katayama et al., 1991) . For this purpose various quantitative methods for measuring FN concentration have been developed.
Only recently, have specific antibodies made it possible to study the cellular form of FN containing the EDA sequence. In immunohistochemical stainings, EDAcFN has been shown to be abundantly present in certain developing basement membranes and in reactive adult tissues (Vartio et al., 1987; Virtanen et al., 1988; Gould et al., 1990; Laitinen et al., 1991) . EDAcFN also showed a strong expression in the stroma of all studied carcinomas (Vartio et al., 1987 Laemmli, 1970) was performed using 6.5% vertical slab gels under reducing conditions. After electrophoresis, the gels were either protein stained (Fairbanks et al., 1971) or subjected to Western blotting (Towbin et al., 1979) by transferring SDS-PAGE-separated polypeptides onto nitrocellulose sheets. Immunoreactions were detected by peroxidasecoupled MAbs DH1 or BF12.
Statistical analysis
The Mann-Whitney U-test (the two-tailed test) was used to obtain the probability (P) values of the data measured. Probability values less than 0.05 were considered significant.
Receiver operating charactenrstic (ROC) curves were constructed by calculating the true-positive fraction and falsepositive fraction of EDAcFN in plasma and serum at several cut-off points. cFN in plasma and serun of healthy blood donors The EDAcFN concentration in plasma and serum samples was determined using competitive EDAcFN EIA as described previously (Ylatupa et al., 1993) . The coefficient of variation (CV) for measurement of both inter-assay and intra-assay standards (n = 6) and samples (n =4) was less than 10%. The intra-assay CV varied between 2.0% and 7.0% and the inter-assay CV ranged between 4.0% and 8.0%. In plasma from healthy blood donors, the mean concentration of EDAcFN was 2.46± 1.99 mgl'. The mean serum concentration was 0.30 ± 0.51 mg 1-In men, the mean concentrations of EDAcFN in plasma and serum were 2.65 ± 2.09 mg I`(n = 244) and 0.32 ± 0.56 mg 1`(n = 169) respectively, and in women 2.08 ± 1.83 mg 1-l (n = 235) and 0.28 ± 0.43 mg 1' (n = 131) respectively. The differences between sexes were not statistically significant. In similar fashion, significant differences were not apparent between groups of subjects aged 18-35 years (plasma 1.77± 1.74mg 1-l, n= 161; serum 0.31 ± 0.55mgl-', n=97), [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] (Figure 2) . Figure 3a shows the receiver operating curves (ROC) of EDAcFN in serum and plasma from healthy blood donors and cancer patients with digestive tract and miscellaneous malignancies. Both curves behave similarly, but the truepositive fraction, i.e. the sensitivity, was slightly higher for plasma samples than for serum samples. However, in spite of the higher concentrations of EDAcFN in plasma than in serum, the true-positive fraction in patients with breast cancer was significantly higher for serum (Figure 3b) Figure   4 ).
Numerous studies have evaluated whether FN levels in plasma or other body fluids might be indicative of cancer or other clinical conditions. The results have been contradictory. High plasma levels of total FN have been reported in patients with breast, ovarian, lung, pancreatic and colonic carcinoma (Mosher and Williams, 1978; Parsons et al., 1979a,b; Todd et al., 1980; Choate and Mosher, 1983) , whereas reduced levels of FN have been reported in plasma of patients with lymphatic leukaemia (Bruhn and Heimburger, 1976) and haemopathic diseases (De Russe et al., 1985) . Interestingly, the latter diseases differ from carcinomas in that they lack a stromal response. On the other hand, Eijan et al. (1986) found no clear correlation between FN levels and breast cancer, and normal FN concentrations have also been reported in patients with acute leukaemia, lacking the stromal response (Choate and Mosher, 1983 al., 1988, 1989) or as a predictor of preterm delivery (Lockwood et al., 1991) . Recently, we described an EIA detecting EDAcFN (Ylatupa et al., 1993) . In this study, the normal values of EDAcFN in plasma and serum were determined by studying blood donors. Low concentrations of EDAcFN were found
Fige 4 Western blot analysis of EDAcFN and total FN in plasma and serum samples from a healthy blood donor and from a patient with gastrointestinal carcinoma. Lanes 1-5, the MAb DHI-reactive EDAcFN; lanes 6-9, BF12-reactive total FN. Lane 1, a purified standard cFN; lanes 2 and 6, serum of the carcinoma patient; lanes 3 and 7, plasma from the carcinoma patient; lanes 4 and 8, plasma from a healthy blood donor; lanes 5 and 9, serum from a healthy blood donor.
in both plasma and serum of healthy individuals. The concentration in serum was clearly lower than in plasma, which apparently is due to binding of FN to fibrin in blood clotting (Engvall et al., 1978) . It has previously been shown that the levels of total FN in plasma increase significantly with age and that there are minor differences in total FN concentrations between men and women (Fyrand and Solumn, 1976; Peters et al., 1989) . However, the concentrations of EDAcFN in serum and plasma seem to be independent of sex and age. Our observations are in concordance with those of Peters et al. (1989) .
Immunohistochemically, a strong expression of EDAcFN has been shown in malignant tumours using the monoclonal antibody DHI against the EDA domain of cFN (Vartio et al., 1987; Gould et al., 1990) . In this study we performed a preliminary evaluation of the potential utility of our new assay as a plasma and/or serum tumour marker by determining the EDAcFN levels in 120 cancer patients. A majority of patients with gastrointestinal cancers showed elevated values in both plasma and serum. The same was true for a small group of miscellaneous tumours, including lung, kidney, liver, bladder and a few other cancers. In spite of the higher concentrations found in plasma, the sensitivity of the test, when the 97.5% level of blood donors were used as a cut-off level, was similar in plasma and serum. In breast cancer, however, there was a difference between plasma and serum. Sixty per cent of the patients had an elevated serum level of EDAcFN, whereas the concentration in plasma was low in most patients. On the other hand, the elevated serum levels in many breast cancer patients were only slightly above the cut-off level, and in 30% of patients with benign diseases the serum level exceeded the cut-off level. In plasma samples from all patients with benign disease the concentration remained below the cut-off level.
Since the levels of various tumour markers are often increased during pregnancy, EDAcFN was measured in 20 plasma samples from pregnant women. The mean concentration was higher than that of healthy blood donors, but remained clearly below the cut-off level of normal subjects. 
